Eli Lilly Delivers Positive Clinical Outcomes Across Diverse Pipeline

The pharmaceutical leader reports strong performance beyond its weight-loss drug portfolio.

Published on Feb. 15, 2026

Got story updates? Submit your updates here. ›

Eli Lilly, the pharmaceutical company known for its successful weight-loss and diabetes drugs, has recently reported positive clinical outcomes across a diverse range of its drug pipeline. According to the company's chief scientific and medical officer, Daniel Skovronsky, Eli Lilly "achieved positive outcomes for nearly all R&D key events in 2025," a rare feat in the industry. This includes not only progress in the company's weight management and diabetes therapies, but also advancements in cancer and Alzheimer's disease treatments.

Why it matters

Eli Lilly's ability to achieve positive clinical results across its diverse pipeline, beyond just its weight-loss and diabetes drugs, demonstrates the company's innovative capabilities and strong research and development efforts. This diversification reduces the company's reliance on any single product or therapeutic area, making it a more resilient and attractive investment option for investors.

The details

In addition to the success of its weight-loss drug retatrutide and oral GLP-1 medication orforglipron, Eli Lilly also reported positive phase 3 results for its cancer drug Jaypirca and promising long-term data for its Alzheimer's disease treatment Kisunla. The company is also investing in artificial intelligence (AI) to further improve its clinical trial success rate, building what will become the industry's largest AI supercomputer.

  • In 2025, Eli Lilly reported positive outcomes for nearly all of its key R&D events.
  • Eli Lilly's retatrutide and orforglipron performed well in phase 3 clinical studies.
  • Eli Lilly's cancer drug Jaypirca aced a phase 3 study in 2025.
  • Eli Lilly's Alzheimer's disease treatment Kisunla showed promise in slowing cognitive decline in a long-term study in 2025.

The players

Eli Lilly

A leading pharmaceutical company known for its diabetes and weight-loss drug portfolio, as well as its broader innovative pipeline.

Daniel Skovronsky

Eli Lilly's chief scientific and medical officer, who reported the company's strong clinical execution across its R&D pipeline.

Got photos? Submit your photos here. ›

What they’re saying

“We [Eli Lilly] achieved positive outcomes for nearly all R&D key events in 2025, a rare set of results in this industry.”

— Daniel Skovronsky, Chief Scientific and Medical Officer (Yahoo Finance)

What’s next

Eli Lilly is investing in artificial intelligence (AI) to further improve its clinical trial success rate, including building what will become the industry's largest AI supercomputer.

The takeaway

Eli Lilly's ability to deliver positive clinical results across a diverse range of therapies, from weight-loss and diabetes to cancer and Alzheimer's disease, demonstrates the company's innovative capabilities and strong research and development efforts, making it an attractive investment option for investors seeking a resilient pharmaceutical company.